Related Experiment Video
Updated: Dec 16, 2025

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Reduced replication origin licensing selectively kills KRAS-mutant colorectal cancer cells via mitotic catastrophe
Bastian Gastl1,2, Kathleen Klotz-Noack1,3, Bertram Klinger1,4
1Institute of Pathology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Abstract:
To unravel vulnerabilities of KRAS-mutant CRC cells, a shRNA-based screen specifically inhibiting MAPK pathway components and targets was performed in CaCo2 cells harboring conditional oncogenic KRASG12V. The custom-designed shRNA library comprised 121 selected genes, which were previously identified to be strongly regulated in response to MEK inhibition. The screen showed that CaCo2 cells expressing KRASG12V were sensitive to the suppression of the DNA replication licensing factor minichromosome maintenance complex component 7 (MCM7), whereas KRASwt CaCo2 cells were largely resistant to MCM7 suppression. Similar results were obtained in an isogenic DLD-1 cell culture model. Knockdown of MCM7 in a KRAS-mutant background led to replication stress as indicated by increased nuclear RPA focalization. Further investigation showed a significant increase in mitotic cells after simultaneous MCM7 knockdown and KRASG12V expression. The increased percentage of mitotic cells coincided with strongly increased DNA damage in mitosis. Taken together, the accumulation of DNA damage in mitotic cells is due to replication stress that remained unresolved, which results in mitotic catastrophe and cell death. In summary, the data show a vulnerability of KRAS-mutant cells towards suppression of MCM7 and suggest that inhibiting DNA replication licensing might be a viable strategy to target KRAS-mutant cancers.
Insights
KRAS-mutant colorectal cancer (CRC) cells show vulnerability to suppression of minichromosome maintenance complex component 7 (MCM7). Targeting DNA replication licensing via MCM7 inhibition offers a potential therapeutic strategy for KRAS-mutant cancers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- KRAS mutations are common drivers in colorectal cancer (CRC).
- Identifying specific vulnerabilities in KRAS-mutant CRC cells is crucial for developing targeted therapies.
- The MAPK pathway is frequently dysregulated in KRAS-mutant cancers.
Purpose of the Study:
- To identify novel therapeutic targets in KRAS-mutant CRC cells.
- To investigate the role of DNA replication licensing in KRAS-mutant CRC vulnerabilities.
- To explore the potential of targeting MCM7 for cancer therapy.
Main Methods:
- Conducted an shRNA-based screen targeting MAPK pathway components in KRAS-mutant CaCo2 cells.
- Utilized a custom shRNA library of 121 genes regulated by MEK inhibition.
- Validated findings in an isogenic DLD-1 cell culture model.
Main Results:
- KRAS-mutant cells exhibited sensitivity to the suppression of minichromosome maintenance complex component 7 (MCM7).
- MCM7 knockdown in KRAS-mutant cells induced replication stress and DNA damage during mitosis.
- Unresolved replication stress led to mitotic catastrophe and cell death.
Conclusions:
- KRAS-mutant CRC cells are uniquely vulnerable to MCM7 suppression.
- Inhibiting DNA replication licensing represents a promising therapeutic strategy for KRAS-mutant cancers.
- MCM7 is a potential therapeutic target for KRAS-driven malignancies.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Related Concept Videos
Replicative Cell Senescence
The Ras Gene
Ras is a...
Cancers Originate from Somatic Mutations in a Single Cell
S-Cdk Initiates DNA Replication
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of...
Restarting Stalled Replication Forks
Targeted Cancer Therapies
There are several types of targeted therapies against...